AR055075A1 - Metodos y composiciones para tratar trastornos oftalmicos mediante la modulacion del retinol en suero proteina enlazante de retinol en suero (rbp) y/o retinol rbp en suero - Google Patents

Metodos y composiciones para tratar trastornos oftalmicos mediante la modulacion del retinol en suero proteina enlazante de retinol en suero (rbp) y/o retinol rbp en suero

Info

Publication number
AR055075A1
AR055075A1 ARP060102980A ARP060102980A AR055075A1 AR 055075 A1 AR055075 A1 AR 055075A1 AR P060102980 A ARP060102980 A AR P060102980A AR P060102980 A ARP060102980 A AR P060102980A AR 055075 A1 AR055075 A1 AR 055075A1
Authority
AR
Argentina
Prior art keywords
retinol
serum
rbp
compositions
ophthalmic disorders
Prior art date
Application number
ARP060102980A
Other languages
English (en)
Original Assignee
Sytera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sytera Inc filed Critical Sytera Inc
Publication of AR055075A1 publication Critical patent/AR055075A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Husbandry (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

Se pueden usar compuestos que reducen los niveles de retinol en suero, RBP en suero y/o retinol RBP en suero para tratar trastornos oftálmicos asociados con la sobreproduccion de productos de desecho que se acumulan durante el curso del ciclo visual. Se describen métodos y composiciones usando tales compuestos y sus derivados para tratar, por ejemplo la degeneracion macular y las distrofias o para aliviar síntomas asociados con tales trastornos oftálmicos. Tales compuestos y sus derivados pueden usarse como terapia de agente unico o en combinacion con otros agentes o terapias.
ARP060102980A 2005-07-11 2006-07-11 Metodos y composiciones para tratar trastornos oftalmicos mediante la modulacion del retinol en suero proteina enlazante de retinol en suero (rbp) y/o retinol rbp en suero AR055075A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69851205P 2005-07-11 2005-07-11

Publications (1)

Publication Number Publication Date
AR055075A1 true AR055075A1 (es) 2007-08-01

Family

ID=36955418

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102980A AR055075A1 (es) 2005-07-11 2006-07-11 Metodos y composiciones para tratar trastornos oftalmicos mediante la modulacion del retinol en suero proteina enlazante de retinol en suero (rbp) y/o retinol rbp en suero

Country Status (19)

Country Link
US (2) US20070015827A1 (es)
EP (1) EP1904043A4 (es)
JP (1) JP2009500455A (es)
KR (1) KR20080055790A (es)
CN (1) CN101252924B (es)
AR (1) AR055075A1 (es)
AU (1) AU2006268374A1 (es)
BR (1) BRPI0612405A2 (es)
CA (1) CA2614627C (es)
EA (1) EA200800291A1 (es)
GB (1) GB2428975B (es)
HK (1) HK1122744A1 (es)
IL (1) IL188528A0 (es)
MX (1) MX2008000064A (es)
NO (1) NO20080718L (es)
TW (1) TW200727894A (es)
UA (1) UA81382C2 (es)
WO (1) WO2007008821A2 (es)
ZA (1) ZA200800844B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1768657B1 (en) * 2004-06-23 2008-08-13 Sirion Therapeutics, Inc. Methods and compositions for treating ophthalmic conditions with retinyl derivates
EP1807103A4 (en) * 2004-11-04 2009-02-11 Sirion Therapeutics Inc MODULATORS OF A COMPLEX RETINOL-RETINOL-BINDING PROTEIN-TRANSTHYRETINE FORMATION
EA011154B1 (ru) * 2004-12-08 2009-02-27 Сирион Терапьютикс, Инк. Композиции для лечения ретинол-ассоциированных заболеваний
US8877809B2 (en) * 2007-09-12 2014-11-04 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating macular degeneration
CN101229147B (zh) * 2007-12-24 2010-09-01 复旦大学 N-4-羟苯视黄酰胺在制备抗肝纤维化药物中的用途
US20110210074A1 (en) * 2008-06-26 2011-09-01 Winchester James F Removal of myoglobin from blood and/or physiological fluids
JP5951625B2 (ja) 2010-11-24 2016-07-13 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨークＴｈｅ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｃｏｌｕｍｂｉａ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎ Ｔｈｅ Ｃｉｔｙ Ｏｆ Ｎｅｗ Ｙｏｒｋ 加齢性黄斑変性症およびシュタルガルト病の処置のための非レチノイドｒｂｐ４アンタゴニスト
WO2012078525A2 (en) * 2010-12-06 2012-06-14 Revision Therapeutics, Inc. Compositions and methods for treating ophthalmic conditions
WO2013166041A1 (en) * 2012-05-01 2013-11-07 The Trustees Of Columbia University In The City Of New York Transthyretin ligands capable of inhibiting retinol-dependent rbp4-ttr interaction for treatment of age-related macular
US9333202B2 (en) 2012-05-01 2016-05-10 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
US10092393B2 (en) 2013-03-14 2018-10-09 Allotex, Inc. Corneal implant systems and methods
EP3495357B1 (en) 2013-03-14 2021-05-05 The Trustees of Columbia University in the City of New York 4-phenylpiperidines, their preparation and use
US9944644B2 (en) 2013-03-14 2018-04-17 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles their preparation and use
US9637450B2 (en) 2013-03-14 2017-05-02 The Trustees Of Columbia University In The City Of New York Octahydrocyclopentapyrroles, their preparation and use
US9938291B2 (en) 2013-03-14 2018-04-10 The Trustess Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
ES2896173T3 (es) * 2014-02-13 2022-02-24 Katairo Gmbh Procedimientos para la determinación de compuestos o composiciones para el tratamiento de enfermedades relacionadas con la lipofuscina y compuestos o composiciones
KR102429220B1 (ko) 2014-04-30 2022-08-04 더 트러스티이스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 치환 4-페닐피페리딘, 그 제조 및 사용
US10449090B2 (en) 2015-07-31 2019-10-22 Allotex, Inc. Corneal implant systems and methods
GB201706009D0 (en) * 2017-04-13 2017-05-31 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of stargardt disease

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2004A (en) * 1841-03-12 Improvement in the manner of constructing and propelling steam-vessels
US4190594A (en) * 1975-11-03 1980-02-26 Johnson & Johnson Retinoic acid derivatives
US4323581A (en) * 1978-07-31 1982-04-06 Johnson & Johnson Method of treating carcinogenesis
US4665098A (en) * 1985-03-28 1987-05-12 Mcneilab, Inc. Pharmaceutical composition of N-(4-hydroxyphenyl) retinamide having increased bioavailability
US4874795A (en) * 1985-04-02 1989-10-17 Yesair David W Composition for delivery of orally administered drugs and other substances
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4743400A (en) * 1986-09-22 1988-05-10 Mcneilab, Inc. Process for preparing retinoyl chlorides
US5814612A (en) * 1991-04-09 1998-09-29 Sloan-Kettering Institute For Cancer Research Retinol derivatives and uses thereof
US6992108B1 (en) * 1991-12-18 2006-01-31 The Salk Institute For Biological Studies Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor
US6093706A (en) * 1992-03-04 2000-07-25 Bioresponse, L.L.C. Combined dehydroepiandrosterone and retinoid therapy for epithelial disorders
US5314909A (en) * 1993-03-17 1994-05-24 Merck & Co., Inc. Use of non-steroidal antiiflammatory agents in macular degeneration
US5399757A (en) * 1993-07-20 1995-03-21 Ortho Pharmaceutical Corporation Process for the preparation of N-(4-hydroxyphenyl)-retinamide
US5427571A (en) * 1994-08-08 1995-06-27 Cor-A-Vent Incorporated Ventilated cap system for the ridge of a roof
US5824685A (en) * 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
US5596011A (en) * 1995-04-06 1997-01-21 Repine; Karen M. Method for the treatment of macular degeneration
US5846220A (en) * 1996-04-30 1998-12-08 Medtronic, Inc. Therapeutic method for treatment of Alzheimer's disease
US6034211A (en) * 1996-06-03 2000-03-07 Kelly; Jeffery W. β-sheet nucleating peptidomimetics
US5955305A (en) * 1997-04-28 1999-09-21 Incyte Pharmaceuticals, Inc. Human retinoid binding protein
US5776915A (en) * 1997-08-12 1998-07-07 Clarion Pharmaceuticals Inc. Phosphocholines of retinoids
WO1999008682A1 (en) * 1997-08-15 1999-02-25 Duke University A method of preventing or treating estrogen-dependent diseases and disorders
CA2331620A1 (en) * 1998-05-11 1999-11-18 The Endowment For Research In Human Biology, Inc. Use of neomycin for treating angiogenesis-related diseases
EP1153248B1 (en) * 1998-12-17 2006-04-19 Diversi-Plast Products Inc. Ridge cap vent
US6128870A (en) * 1999-05-24 2000-10-10 Kohler; Raymond L. Roof vent system
US7229961B2 (en) * 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US20020031539A1 (en) * 2000-08-30 2002-03-14 The Brigham And Women's Hospital, Inc. Oxidized forms of retinoic acid as ligands for peroxisome proliferator activated receptor gamma
US6450882B1 (en) * 2000-08-30 2002-09-17 Liberty Diversified Industries, Inc. Precipitation resistant ridge vent
WO2002032413A2 (en) * 2000-10-17 2002-04-25 Board Of Regents, The University Of Texas System A method to incorporate n-(4-hydroxyphenyl) retinamide in liposomes
DE60136648D1 (de) * 2000-12-05 2009-01-02 Los Angeles Childrens Hospital Pharmazeutische zusammensetzungen von fenretinid mit erhöhter bioverfügbarkeit und verfahren zu deren verwendung
US20030032078A1 (en) * 2001-01-23 2003-02-13 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of macular and retinal degenerations
CA2450656A1 (en) * 2001-06-15 2002-12-27 The Cleveland Clinic Foundation Ratiometric quantitation of elicited eye autofluorescence
DE60208792T2 (de) * 2001-06-22 2006-08-31 Merck & Co., Inc. Tyrosin-kinase inhibitoren
WO2003003987A2 (en) * 2001-07-06 2003-01-16 The Ohio State University Research Foundation Solid phase synthesis of arylretinamides
WO2003007944A1 (en) * 2001-07-20 2003-01-30 Qlt, Inc. Treatment of macular edema with photodynamic therapy
US7595430B2 (en) * 2002-10-30 2009-09-29 University Of Kentucky Research Foundation Methods and animal model for analyzing age-related macular degeneration
US7354574B2 (en) * 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
KR20060135819A (ko) * 2004-02-17 2006-12-29 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 황반변성을 포함하는 안과질환의 관리
US7566808B2 (en) * 2004-02-17 2009-07-28 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
EP1768657B1 (en) * 2004-06-23 2008-08-13 Sirion Therapeutics, Inc. Methods and compositions for treating ophthalmic conditions with retinyl derivates
AU2005287343A1 (en) * 2004-08-18 2006-03-30 Sirion Therapeutics, Inc. Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat opthalmic disorders
EP1807103A4 (en) * 2004-11-04 2009-02-11 Sirion Therapeutics Inc MODULATORS OF A COMPLEX RETINOL-RETINOL-BINDING PROTEIN-TRANSTHYRETINE FORMATION
EA011154B1 (ru) * 2004-12-08 2009-02-27 Сирион Терапьютикс, Инк. Композиции для лечения ретинол-ассоциированных заболеваний

Also Published As

Publication number Publication date
EA200800291A1 (ru) 2008-06-30
GB0613730D0 (en) 2006-08-23
AU2006268374A1 (en) 2007-01-18
WO2007008821A3 (en) 2007-07-12
CA2614627C (en) 2013-11-19
BRPI0612405A2 (pt) 2012-04-24
TW200727894A (en) 2007-08-01
CN101252924A (zh) 2008-08-27
MX2008000064A (es) 2008-04-07
AU2006268374A2 (en) 2008-05-22
KR20080055790A (ko) 2008-06-19
ZA200800844B (en) 2009-04-29
GB2428975A (en) 2007-02-14
JP2009500455A (ja) 2009-01-08
UA81382C2 (en) 2007-12-25
IL188528A0 (en) 2008-04-13
US20070015827A1 (en) 2007-01-18
EP1904043A4 (en) 2008-09-17
NO20080718L (no) 2008-04-02
US20120288568A1 (en) 2012-11-15
GB2428975B (en) 2008-08-13
EP1904043A2 (en) 2008-04-02
CA2614627A1 (en) 2007-01-18
CN101252924B (zh) 2013-06-19
AU2006268374A8 (en) 2008-03-20
HK1122744A1 (en) 2009-05-29
WO2007008821A2 (en) 2007-01-18

Similar Documents

Publication Publication Date Title
AR055075A1 (es) Metodos y composiciones para tratar trastornos oftalmicos mediante la modulacion del retinol en suero proteina enlazante de retinol en suero (rbp) y/o retinol rbp en suero
AR049929A1 (es) Metodos y composiciones para el tratamiento de afecciones oftalmicas con derivados de retinilo
ECSP10010372A (es) Métodos y composiciones que utilizan polipéptidos de fusión de klotho-fgf
MX2021005887A (es) Compuestos de 2-formil-3-hidroxifeniloximetilo capaces de modular hemoglobina.
ECSP099688A (es) Moléculas y métodos para modular la pro-proteína
AR100562A1 (es) Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
BR112016012968A2 (pt) Métodos e composições para o tratamento de condições associadas com o envelhecimento
BR112016029906A2 (pt) compostos excipientes redutores de viscosidade para formulações proteicas
NO20070330L (no) Retinalderivater og fremgangsmater for anvendelse derav til behandling av synsforstyrrelser
NO20073510L (no) Metoder, bestemmelser og preparater for behandling av retinolrelaterte sykdommer
IN2012DN00352A (es)
AR059555A1 (es) Metodos para el tratamiento de degeneracion macular y condiciones oculares relacionadas
GT200600115A (es) Metodo para identificar blancos terapeuticos para el tratamiento de atrofia vulvoginal
ECSP14000606A (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
DOP2013000218A (es) Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi)
EA201391407A1 (ru) Композиции для лечения нервных расстройств
TR201819781T4 (tr) Kanama Bozukluklarının Tedavisi İçin Modifiye Serpinler
WO2015142500A3 (en) Compositions and methods for treating addiction
WO2009042444A3 (en) Methods and compounds for treating retinol-related diseases
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
CO2021001172A2 (es) Composiciones y métodos para el tratamiento de enfermedades o condiciones relacionadas con inflamasomas
CY1125113T1 (el) Συνθεσεις και μεθοδοι για χρηση στην αγωγη της ομοκυστινουριας
BR112017007138A2 (pt) composto, medicamento, métodos para reduzir proteína 4 de ligação ao retinol e para a profilaxia ou o tratamento de degeneração macular e/ou uma doença, e, uso de um composto.
CO2022007814A2 (es) Ligandos de la pseudoquinasa tyk2
BR112019000635A2 (pt) inibidor de receptor 2 do tipo toll (tlr2) e seu uso, anticorpo, composição e método para tratar uma afecção inflamatória

Legal Events

Date Code Title Description
FA Abandonment or withdrawal